MAIDENHEAD, UK, 10th March, 2020 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today hosted a Showcase on Shared Decision Making, which highlighted the importance of patients being involved in decisions made about their care.
The showcase took place just over one year after the launch of the NHS Long Term Plan and Universal Personalised Care Plan which established ambitious targets to put shared decision making at the heart of patient care.
The showcase provided a platform for patient groups, NHS Trusts, and healthcare providers to share their innovative work. With projects from therapy areas such as MS, arthritis, Lymphoma, Autism, Hepatitis C, kidney dialysis and more. All focused on empowering patients to take an active part in decisions about their treatment and care.
The event was attended by Parliamentarians, policy makers and national NHS bodies.
Professor Matthew Cripps, Director of Sustainable Healthcare at NHS England & NHS Improvement who opened the event said, “Chapter one of the NHS Long Term Plan makes personalised care business as usual across the health and care system. At NHS England, we’re working to make this a reality, and shared decision making is a key component of this. This showcase has demonstrated how putting patients at the center of their care has a significant impact on outcomes for patients.”
Todd Manning, UK General Manager, AbbVie stated: “AbbVie is committed to working with key partners across the health and care system, with the aim of ensuring patients are involved in the decisions made about their care. For example, we’ve supported projects to develop patient information and those like the Picker Institute survey on shared decision making in dermatology which identified a lack of patients’ involvementin decisions about their care, as showcased at this year’s Shared Decision Making Showcase. In 2020 we will call for policy reform with an aim to embed shared decision making across the NHS.”
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.